YPT35 Antibody

What is VP35 and why is it a significant target for antibody development?

VP35 is a viral protein from Ebola virus (EBOV) that serves dual essential functions: it acts as a cofactor in the viral polymerase complex critical for viral replication and functions as an Interferon (IFN) antagonist that helps the virus evade host immune responses. VP35 contains an IFN-inhibitory domain (IID) with two key basic regions - one comprising residues K222, R225, K248, and K251 involved in viral polymerase activity, and a central basic patch (R305, K309, R312, R319, R322, K339) primarily involved in IFN inhibition. Developing antibodies against VP35 could potentially inhibit viral replication by disrupting these essential functions, making it a promising target for therapeutic interventions against Ebola virus disease .

What structural features of VP35 are important for antibody recognition?

VP35 contains distinct structural domains that can be targeted by antibodies. The C-terminal region, termed the IFN-inhibitory domain (IID), contains two critical basic regions with distinct functions. The first basic patch includes residues K222, R225, K248, and K251 and is primarily involved in viral polymerase activity. The second central basic patch includes residues R305, K309, R312, R319, R322, and K339, which primarily functions in IFN inhibition but can also affect polymerase activity. Importantly, mutations disrupting the basic charge on R225 have been shown to decrease VP35 polymerase cofactor activity, potentially due to loss of interaction with nucleoprotein (NP) . These distinct structural regions provide potential epitopes for antibody recognition and functional inhibition.

How are antibodies against viral proteins like VP35 typically detected in research settings?

Researchers employ several methods to detect antibodies against viral proteins:

• Co-immunoprecipitation (co-IP) assays: These detect protein-antibody binding and associated proteins, as demonstrated in studies of VP35's interaction with ubiquitin .

• Immunoblotting (IB): Used following co-IP to visualize and confirm antibody-protein complexes.

• Cell-based neutralizing antibody assays: These measure functional inhibition, similar to the assay used for anti-IL-21 antibodies where phosphorylation of STAT3 was measured using MSD kits .

• Sandwich immunoassays: These can measure antibody levels in serum with high specificity, using capture and detection antibodies, similar to the method described for AMG 256 measurement .

*Based on sensitivity values reported for anti-IL-21 antibody assays

How does VP35 interact with the ubiquitin system and how can antibodies be used to study these interactions?

VP35 interacts with the ubiquitin system in two distinct ways: through covalent ubiquitination on specific residues (e.g., K309) and through non-covalent interaction with free K63-linked polyubiquitin chains. These non-covalent interactions with unanchored polyubiquitin chains promote efficient viral polymerase function and EBOV replication. Researchers have demonstrated this interaction using co-immunoprecipitation assays with VP35 and either wild-type ubiquitin or a mutant ubiquitin lacking the C-terminal di-glycine residues (HA-Ub-ΔGG), which cannot form covalent linkages .

To study these interactions, researchers can:

• Use co-IP assays with antibodies against VP35 to pull down ubiquitin-associated complexes

• Employ antibodies that recognize specific ubiquitin chain linkages (e.g., K63-linked chains)

• Develop antibodies targeting the ubiquitin-binding interface on VP35

• Use antibodies in competition assays with compounds (like pCEBS and SFC) that disrupt VP35-ubiquitin interactions

What methods are used to study antibody specificity and cross-reactivity with similar viral epitopes?

Researchers employ several sophisticated approaches to study antibody specificity:

• Phage display experiments with selective pressures against different combinations of ligands to identify antibodies with specific binding profiles. In these experiments, antibody libraries (such as a minimal antibody library with systematically varied CDR3 positions) are exposed to different target antigens, and binding antibodies are selected and amplified .

• High-throughput sequencing analysis of selected antibody populations to identify sequence patterns associated with specific binding properties .

• Computational models that identify different binding modes associated with specific ligands, enabling prediction of antibody specificity profiles beyond those observed experimentally .

• Validation experiments with newly generated antibodies to confirm predicted specificity profiles, including both cross-specific (interacting with several distinct ligands) and specific (interacting with a single ligand while excluding others) binding properties .

How can researchers distinguish between antibodies that inhibit different functions of VP35?

VP35 performs multiple functions including viral polymerase cofactor activity and interferon antagonism. Researchers can distinguish between antibodies that inhibit different functions using:

• Minigenome assays: These measure viral polymerase activity and can detect inhibition of VP35's polymerase cofactor function. Researchers have used this approach to demonstrate that compounds that disrupt VP35-ubiquitin interactions reduce polymerase activity .

• Interferon pathway reporter assays: These measure VP35's ability to block interferon signaling and can identify antibodies that restore this immune response.

• Protein-interaction assays: Co-IP studies can determine if antibodies disrupt specific protein-protein interactions, such as VP35's interaction with ubiquitin chains or viral nucleoprotein .

• Virus replication assays: Plaque reduction and virus yield reduction assays directly measure the impact on viral replication, as demonstrated with compounds that disrupt VP35-ubiquitin interactions .

What computational approaches can be used to design antibodies with customized specificity against VP35?

Advanced computational approaches can design antibodies with customized specificity profiles:

• Biophysics-informed modeling: These models associate distinct binding modes with different ligands, allowing prediction of antibody specificity beyond experimentally observed variants. This approach has been used to disentangle multiple binding modes associated with specific ligands, enabling the design of antibodies with either specific binding to particular targets or cross-specificity for multiple targets .

• Energy function optimization: By optimizing the energy functions associated with each binding mode, researchers can generate novel antibody sequences with predefined binding profiles. For cross-specific sequences, researchers jointly minimize the energy functions associated with desired ligands, while for specific sequences, they minimize energy functions for desired ligands while maximizing those for undesired ligands .

• Structure-based design: Computational docking and binding site similarity analysis can identify small molecules that might disrupt specific interactions, as demonstrated with the compounds pCEBS and SFC that disrupt VP35-ubiquitin interactions. Similar approaches could be applied to antibody design .

• Machine learning approaches trained on phage display experimental data: These can identify antibody sequence patterns associated with specific binding properties and generate novel sequences with desired characteristics .

How can researchers evaluate the potential therapeutic efficacy of antibodies targeting VP35?

Evaluating potential therapeutic efficacy of anti-VP35 antibodies requires multiple approaches:

• Biochemical inhibition assays: Assess whether antibodies block specific interactions critical for VP35 function, such as the non-covalent interaction with ubiquitin chains. Researchers can quantify this inhibition as demonstrated with small molecule inhibitors pCEBS and SFC, which reduced VP35-ubiquitin interactions at specific concentrations .

• Functional inhibition assays: Minigenome experiments measuring luciferase activity can determine if antibodies impair VP35's polymerase cofactor function. In studies with small molecule inhibitors, decreased ubiquitin-VP35 interactions correlated with decreased luciferase activity in minigenome experiments .

• Virus replication assays: Plaque reduction and virus yield reduction assays directly measure the impact on viral replication in cellular systems. These assays have demonstrated that disrupting VP35-ubiquitin interactions reduces infectious EBOV replication .

• Cytotoxicity assessment: Evaluating potential side effects of antibody treatments is essential, as demonstrated in the evaluation of compounds targeting VP35-ubiquitin interactions, which showed less than 5% cell death in cytotoxicity assays .

What strategies exist for developing antibodies that specifically disrupt protein-ubiquitin interactions?

Developing antibodies that specifically disrupt protein-ubiquitin interactions requires specialized approaches:

• Structural targeting: Design antibodies targeting specific cavities on VP35 that are involved in ubiquitin binding. The cavity analysis approach used to identify small molecules pCEBS and SFC could inform epitope targeting for antibody development .

• Competitive binding assays: Screen antibody libraries for variants that compete with ubiquitin for binding to VP35, similar to how small molecules were tested for their ability to disrupt VP35-ubiquitin interactions .

• Mutational analysis: Generate antibodies targeting specific residues known to be critical for ubiquitin binding, such as the R225 residue of VP35, which when mutated (R225E) shows reduced binding to ubiquitin and reduced polymerase activity .

• Biophysics-informed design: Apply computational models that distinguish between different binding modes to design antibodies that specifically recognize the ubiquitin-binding interface without affecting other VP35 functions .

How do post-translational modifications of VP35 affect antibody recognition and function?

Post-translational modifications significantly impact antibody recognition of VP35:

• Ubiquitination patterns: VP35 undergoes both covalent ubiquitination and non-covalent interaction with ubiquitin chains. These modifications alter protein conformation and function, potentially creating or masking antibody epitopes. Research has shown that covalent ubiquitination on K309 and non-covalent interaction with K63-linked polyubiquitin chains both regulate VP35 function .

• Modification-specific antibodies: Researchers can develop antibodies that specifically recognize ubiquitinated forms of VP35 versus non-modified forms, providing tools to study the dynamics of these modifications during viral infection.

• Functional impact: Antibodies targeting modification sites may have different functional effects depending on the modification state of VP35. For example, antibodies targeting the ubiquitin-binding interface might be more effective against non-covalently ubiquitin-associated VP35 than covalently modified forms .

• Temporal dynamics: The timing of VP35 modifications during infection could affect antibody efficacy, suggesting that combination approaches targeting different modification states might be more effective therapeutic strategies.